• 1. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Research Brief on 3-bromo-5H,7H-furo[3,4-b]pyridine-5,7-dione (CAS: 98278-78-5): Recent Advances and Applications

3-bromo-5H,7H-furo[3,4-b]pyridine-5,7-dione (CAS: 98278-78-5) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential therapeutic applications. Recent studies have explored its utility as a versatile building block for the synthesis of novel bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug discovery.

Recent advancements in synthetic methodologies have enabled more efficient and scalable routes to 3-bromo-5H,7H-furo[3,4-b]pyridine-5,7-dione. A study published in the Journal of Medicinal Chemistry (2023) demonstrated a novel one-pot synthesis approach that significantly improved the yield and purity of the compound. This method utilizes a palladium-catalyzed coupling reaction, which not only reduces the number of synthetic steps but also minimizes the formation of by-products. Such improvements are critical for the large-scale production of this compound, which is increasingly being used as a key intermediate in the synthesis of complex drug candidates.

In terms of biological activity, 3-bromo-5H,7H-furo[3,4-b]pyridine-5,7-dione has shown promising results as a scaffold for kinase inhibitors. A recent study highlighted its role in the development of selective inhibitors for cyclin-dependent kinases (CDKs), which are implicated in various cancers. The bromo-substituted furopyridinedione moiety was found to interact with the ATP-binding site of CDK2, leading to potent inhibition of kinase activity. These findings were supported by molecular docking studies and in vitro assays, which demonstrated low micromolar IC50 values against several cancer cell lines.

Beyond its applications in oncology, 3-bromo-5H,7H-furo[3,4-b]pyridine-5,7-dione has also been investigated for its antimicrobial properties. A 2024 study published in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound exhibited broad-spectrum activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanism of action appears to involve disruption of bacterial cell wall synthesis, as evidenced by electron microscopy and proteomic analyses. These results suggest that this compound could serve as a valuable starting point for the development of new antibiotics to address the growing problem of antimicrobial resistance.

In conclusion, 3-bromo-5H,7H-furo[3,4-b]pyridine-5,7-dione (CAS: 98278-78-5) represents a highly versatile and pharmacologically relevant scaffold in modern drug discovery. Recent research has not only improved its synthetic accessibility but also expanded its potential applications in oncology and infectious disease. Future studies should focus on optimizing its pharmacokinetic properties and exploring its utility in other therapeutic areas, such as neurodegenerative diseases and inflammation. The continued investigation of this compound is likely to yield valuable insights and novel drug candidates in the coming years.

• 98555-51-2(5-Bromopyridine-2,3-dicarboxylic acid)
• 90376-83-3(2-methyl-Furo[3,4-b]pyridine-5,7-dione)
• 892874-36-1(Diethyl 6-bromoquinoline-2,3-dicarboxylate)
• 213771-32-5(methyl 5-bromo-3-methylpyridine-2-carboxylate)
• 794592-13-5(5-Bromo-3-Methylpyridine-2-Carboxylic Acid Ethyl Ester)
• 129477-21-0(ethyl 5-bromo-2-methylpyridine-3-carboxylate)
• 521980-82-5(Dimethyl 5-bromopyridine-2,3-dicarboxylate)
• 699-98-9(5H,7H-furo[3,4-b]pyridine-5,7-dione)
• 112110-17-5(3-methyl-5H,7H-furo3,4-bpyridine-5,7-dione)
• 1215916-40-7(methyl 5-bromo-2-methylpyridine-3-carboxylate)